BACKGROUND: Dietary intake of the marine long-chain n-3 polyunsaturated fatty acids (PUFA) may reduce mortality after a myocardial infarction (MI). This may partly be attributed to their anti-inflammatory properties. AIM OF THE STUDY: To investigate the effect of n-3 PUFA on C-reactive protein (CRP) in patients with a previous MI. METHODS: In a double-blind design, forty-one patients (mean age 63 +/- 7 years) were randomized to receive daily supplements with 5.2 g of n-3 PUFA or olive oil (control). Serum CRP was measured with a highly sensitive assay (hs-CRP) before and after 12 weeks supplements. Compliance was monitored by measuring the incorporation of n-3 PUFA into platelets. RESULTS: The content of n-3 PUFA in platelets increased significantly in the n-3 PUFA supplemented group, whereas no changes were seen in controls. There was a minor increase in hs-CRP in the n-3 PUFA group (2.46 vs. 2.70 mg/l) and a small decrease in hs-CRP in the control group (2.52 vs. 1.67 mg/l). The changes, however, were not statistically significant (P = 0.30 and 0.43, respectively). CONCLUSION: Supplementation with 5.2 g of n-3 PUFA for 12 weeks had no hs-CRP lowering effect in patients with a previous MI.
RCT Entities:
BACKGROUND: Dietary intake of the marine long-chain n-3 polyunsaturated fatty acids (PUFA) may reduce mortality after a myocardial infarction (MI). This may partly be attributed to their anti-inflammatory properties. AIM OF THE STUDY: To investigate the effect of n-3 PUFA on C-reactive protein (CRP) in patients with a previous MI. METHODS: In a double-blind design, forty-one patients (mean age 63 +/- 7 years) were randomized to receive daily supplements with 5.2 g of n-3 PUFA or olive oil (control). Serum CRP was measured with a highly sensitive assay (hs-CRP) before and after 12 weeks supplements. Compliance was monitored by measuring the incorporation of n-3 PUFA into platelets. RESULTS: The content of n-3 PUFA in platelets increased significantly in the n-3 PUFA supplemented group, whereas no changes were seen in controls. There was a minor increase in hs-CRP in the n-3 PUFA group (2.46 vs. 2.70 mg/l) and a small decrease in hs-CRP in the control group (2.52 vs. 1.67 mg/l). The changes, however, were not statistically significant (P = 0.30 and 0.43, respectively). CONCLUSION: Supplementation with 5.2 g of n-3 PUFA for 12 weeks had no hs-CRP lowering effect in patients with a previous MI.
Authors: Thomas A Pearson; George A Mensah; R Wayne Alexander; Jeffrey L Anderson; Richard O Cannon; Michael Criqui; Yazid Y Fadl; Stephen P Fortmann; Yuling Hong; Gary L Myers; Nader Rifai; Sidney C Smith; Kathryn Taubert; Russell P Tracy; Frank Vinicor Journal: Circulation Date: 2003-01-28 Impact factor: 29.690
Authors: M L Burr; A M Fehily; J F Gilbert; S Rogers; R M Holliday; P M Sweetnam; P C Elwood; N M Deadman Journal: Lancet Date: 1989-09-30 Impact factor: 79.321
Authors: Esther Lopez-Garcia; Matthias B Schulze; JoAnn E Manson; James B Meigs; Christine M Albert; Nader Rifai; Walter C Willett; Frank B Hu Journal: J Nutr Date: 2004-07 Impact factor: 4.798
Authors: Mari C W Myhrstad; Kjetil Retterstøl; Vibeke H Telle-Hansen; Inger Ottestad; Bente Halvorsen; Kirsten B Holven; Stine M Ulven Journal: Inflamm Res Date: 2011-01-13 Impact factor: 4.575
Authors: Shirin Jafari Salim; Shahab Alizadeh; Mahmoud Djalali; Ebrahim Nematipour; Mohammad Hassan Javanbakht Journal: Am J Mens Health Date: 2017-08-21
Authors: Martin H de Borst; Leandro C Baia; Ellen K Hoogeveen; Erik J Giltay; Gerjan Navis; Stephan J L Bakker; Johanna M Geleijnse; Daan Kromhout; Sabita S Soedamah-Muthu Journal: Nutrients Date: 2017-11-11 Impact factor: 5.717
Authors: Julicristie M Oliveira; Patrícia H C Rondó; Lourdes R A V Lima; Elizabeth S Fortuna; John S Yudkin Journal: Nutrients Date: 2015-08-05 Impact factor: 5.717